Inclusion Criteria:
* Patients aged ≥ 18 and \< 95 years presenting with one of the following indications:
* Varicose vein embolization:
* Pelvic congestion syndrome (uterine venous engorgement, and/or moderate or severe engorgement of the ovarian plexus, and/or filling of the veins across the midline or filling of vulvar or thigh varicosities, and/or reflux throughout the entire course of the ovarian vein.
* Varicocele (symptomatic varicocele, and/or infertility or subfertility).
* Varicose veins in patients with portal hypertension undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) that require embolization.
* Type II endoleak: Persistent type II endoleak and/or an associated sac expansion \> 5 mm after 6 months or 10 mm after 12 months.
* Insufficient liver remnant requiring portal vein embolization (PVE) before liver resection: Predicted insufficient liver remnant after surgery (≤20% in a normal liver, ≤30% in liver with intermediate disease without cirrhosis, and ≤40% in liver with cirrhosis)
* Active arterial hemorrhage and/or pseudoaneurysm: Uncontrolled massive hemorrhage caused by tumor, trauma or arteriovenous shunt formation (congenital or acquired), and/or up to 3 bleeding sites in the same organ or anatomic region
* Pathologic organ (i.e. non-functioning transplanted kidney, preoperative hip replacement, hypersplenism conditioning low platelet count; excluding brain)
* Hypervascular tumors
* Vascular anomalies
Exclusion Criteria:
* Patients with known hypersensitivity or allergy to amber-20, dimethylsulfoxide (DMSO) solvent, or contrast agent
* Previously failed embolization procedure, except for those treated with coils
* Patient in whom according to the investigator criteria a complete vascular occlusion would not be feasible in a single procedure
* Any condition that exposes the patient to a high risk for complications according to the investigator's criteria (e.g., but not limited to, non-correctable coagulopathy, uncontrolled sepsis, underlying life-threatening condition, etc.)
* Patients participating in another interventional study that has not completed it primary endpoint assessment.
* Pregnant or breastfeeding women.
* Patients unable or unwilling to provide a written informed consent.
* Recurrent varicose vein embolization
* Type II endoleak: with high flow or reflux that cannot be prevented using coils or balloon microcatheter, and high risk of medullar ischemic damage
* Active arterial bleeding and/or pseudo aneurysm with: severe hemodynamical instability (e.g., but not limited to, sustained hypotension \[mean arterial pressure \< 60 mmHg\], tachycardia \>120 beats/minute, requirement of high doses of vasopressors, etc.) at the moment of the procedure, and/or hb \< 8 g/dL before the procedure, and/or retroperitoneal hemorrhages or hemoptysis, identification of spinal or medullar vessels.
* Central nervous system and central circulatory system vascular anomalies.
* Iodine contrast allergy
